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Abstract
Objective: Blocking early C-reactive protein-mediated inflammatory reaction may have therapeutic
implications in improving the prognosis of acute renal failure with severe ischemic-reperfusion
injury. Therefore, the role of serum C-reactive protein in acute renal ischemic-reperfusion injury
was investigated.
Methods: Fourteen New Zealand albino rabbits were selected and divided into a treated and a
control group at random. An acute renal ischemia-reperfusion injury model was induced by clamping
the right renal artery for 45 minutes with simultaneous contralateral nephrectomy, followed by
right renal reperfusion. The treated group was injected with dexamethasone (1 mg/kg) 2 minutes
before renal reperfusion. Serum C-reactive protein, blood urea nitrogen, creatinine, and urine volume
were recorded at designed time phases in both groups. Data were expressed as mean ± standard
deviation and analyzed using the Student’s t test.
Results: In the control group, there was a steady increase of serum C-reactive protein that reached
its peak at 6-hour reperfusion, and a positive correlation between C-reactive protein and blood
urea nitrogen and creatinine (r = 0.62 and 0.53, respectively); there was a negative correlation
between C-reactive protein and urine volume (r = –0.52). Compared with the control group, C-
reactive protein values in the treated group remained mainly in the baseline levels after reperfusion,
with C-reactive protein peaking at 4-hour reperfusion (p<0.01), whereas urine volume increased
significantly (p<0.01).
Conclusions: This study indicates that C-reactive protein is involved in the pathogenesis of acute
renal ischemic-reperfusion injury; blocking early C-reactive protein-mediated inflammatory reaction
may have therapeutic implications in improving the prognosis of acute renal failure with severe
ischemic-reperfusion injury.
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INTRODUCTION
Acute renal failure (ARF) is one of most common and
severe complications in clinical medicine, affecting up
to 5% of all hospitalized patients, with a higher
prevalence of 10% to 30% in patients in critical care
units. Despite advances in the management of critically
ill patients and technological advances in renal re-
placement therapy, the high mortality of patients with
ARF has not changed over the past decades and remains
more than 50% (1). Moreover, as a consequence of more
advanced medical therapy and more complicated surgical
interventions in older and multimorbid patients, the
number of patients with ARF is increasing. In the past
two decades, it has been postulated that ischemia-
reperfusion injury has an important pathogenic role in
ARF. Intracellular calcium overload and oxidative stress
were key deleterious agents (2-4). More recent research
demonstrated that acute phase response, an innate
biological response to a disturbance in homeostasis,
usually causes severe tissue injuries in the early phase
of ischemia until up to 30 hours of reperfusion. This
endogenous protective mechanism may be important in
renal ischemia-reperfusion injury (5-8). We designed an
animal model of acute renal ischemia-reperfusion injury
by clamping the right renal artery for 45 minutes with
simultaneous contralateral nephrectomy, followed by
right renal reperfusion. The role of serum C-reactive
protein (CRP) in acute renal ischemia-reperfusion injury
was explored through analysis of the relationships among
CRP, blood urea nitrogen (BUN), creatinine (Cr), and
urine volume. Dexamethasone was given in the treated
group as an important modulator of CRP synthesis (8-
11).
METHODS
Fourteen New Zealand albino rabbits (provided by the
animal office of Tongji Medical College, Huazhong
University of Science and Technology, Wuhan, Hubei)
were selected and randomized into a treated and a control
group. Their body weights ranged between 1.6 and 2.4
kg. General anesthesia was achieved by pentobarbital
injection (30 mg/kg) through the aural marginal vein.
An incision was made through the abdominal midline;
renal pedicles were exposed fully and dissected free. A
small urine collecting tube was inserted into the upper
portion of the right ureter. Baseline serum and urine
samples were obtained before artery clamping. Left
nephrectomy was performed, and the right renal artery
was clamped for 45 minutes and then released. Urine
volume at designed time phases were recorded,
specifically at the end of 45 minutes of ischemia (0 hour),
and after 2, 4, 6, 8, and 10 hours of reperfusion. Serum
CRP, BUN, and Cr were measured respectively at the
same time point. In the treated group, dexamethasone (1
mg/kg) was given intravenously just 2 minutes before
reperfusion. Serum BUN and Cr levels were measured
by using automated analysis of serum biochemicals
(Hitachi CL7200, Japan) and CRP was measured by
using automated immuno-turbidimetry (America Sigma
Beckman Assay 360, America Sigma, New York). Data
were expressed as mean ± standard deviation and
analyzed using the Student’s t test.
RESULTS
C-reactive protein levels at different time phases
increased significantly in the control group compared
with the treated group (p<0.01) (Table 1). There was a
Table 1. Baseline level and changes of serum CRP at 45-minute ischemia and after reperfusion.
                    Serum CRP levels*
Group N 0 hour 2 hours 4 hours 6 hours 8 hours 10 hours
Control 5.50 ± 0.31 6.34 ± 0.85 10.21 ± 3.91 12.26 ± 2.67 14.27 ± 3.52 10.33 ± 3.76 9.85 ± 1.45
Treated 5.43 ± 0.90 6.42 ± 1.78 7.96 ± 1.86† 8.59 ± 3.23† 7.15 ± 3.58† 5.61 ± 1.59† 6.07 ± 2.61†
N = serum CRP in normal white rabbits; 0 hour = CRP level at the end of ischemia; 2 hours = CRP level at 2 hours after renal reperfusion, etc.
*Data are mean ± standard deviation; n = 7.
†CRP comparison between control and treated groups, p<0.01.
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positive correlation between CRP and BUN and Cr (r =
0.62 and 0.53, respectively), and a negative correlation
between CRP and urine volume (r = –0.52). In the treated
group, CRP correlated with BUN and Cr positively (r =
0.72 and 0.52, respectively), and negatively with urine
volume (r = –0.29). Compared with controls, there was
a statistical significance among CRP, BUN, Cr, and urine
volume (p<0.01) (Tables 2 and 3).
DISCUSSION
Acute phase response is an innate biological response to
a disturbance in homeostasis. C-reactive protein,
fibrinogen, and interleukin-6 are the major inflammation
factors involved in this response (11-14). Of the three,
CRP features a homopentameric structure and calcium-
binding specificity for phosphocholine, and its expression
is regulated mainly at the transcription level with
interleukin-6 being the principal inducer of the gene
during the acute phase (11,12). Recent research dem-
onstrated that acute phase response, an endogenous
protective mechanism, may be important in tissue
ischemia-reperfusion injury (10-14). Although there has
been some research concerning the relationship between
CRP and acute myocardial infarction and acute hepatic
ischemic-reperfusion injury, limited research has been
done on the relationship between CRP and acute renal
ischemic-reperfusion injury. In this study, we explored
the role of CRP in the early phase of reperfusion. The
results shown in Table 1 demonstrate that there was a
steady increase of CRP in the control group and reached
its peak after 6 hours of reperfusion, which is in
accordance with published results (5-8). A massive
production of CRP by innate immune response was
induced by tissue ischemia, and CRP was detected in
damaged tissues (11-14). By binding to apoptotic and
necrotic cells in a calcium-dependent manner, CRP
bound to a multivalent ligand can efficiently initiate the
assembly of a C3 convertase through the classical
pathway and decorate the surface of the ligand with
opsonic complement fragments. Furthermore, CRP
activates neutrophils and generates large amounts of
oxidative stress. This process deprives tissue of important
nutrients such as vitamins A, C, E, B6, and carotenoids
together with trace elements, such as zinc and selenium,
resulting in tissue malnutrition. Tables 2 and 3 reveal
a marked dynamic change in serum BUN, Cr
concentration, and urine volume in controls, reaching a
peak at the sixth hour of reperfusion. In the treated group,
serum BUN and Cr showed only a slight increase,
reaching their peak at the fourth hour of reperfusion.
Compared with the control group, there was a statistical
significance (p<0.01). Furthermore, in the control group,
a positive correlation between CRP and BUN and Cr
was demonstrated (r = 0.62 and 0.53, respectively),
together with a negative correlation between CRP and
urine volume (r = –0.52). In the treated group, CRP
correlated with BUN and Cr positively (r = 0.72 and
0.52, respectively), and negatively with urine volume (r =
–0.29). This suggests that CRP might have a deleterious
role in renal ischemia-reperfusion injury. Previous
studies have demonstrated that dexamethasone is an
important modulator of CRP synthesis and has little effect
on other inflammatory factors (8,15). In this study, CRP
production was suppressed with dexamethasone (Table
Table 2. Baseline level and changes of serum BUN and Cr concentration at 45-minute ischemia and after reperfusion.
N 0 hour 2 hours 4 hours 6 hours 8 hours 10 hours
BUN, mmol/L
  Control 4.60 ± 0.85 7.50 ± 1.30 10.89 ± 3.54 14.79 ± 4.27 19.03 ± 5.19 14.02 ± 2.59 16.32 ± 4.30
  Treated 4.72 ± 0.74 7.64 ± 1.46 9.72 ± 2.13† 8.37 ± 2.27† 7.29 ± 2.39† 6.85 ± 2.38† 6.94 ± 2.51†
Cr, µmol/L
  Control 69.56 ± 8.65 123.4 ± 10.73 148.24 ± 18.75 270.88 ± 27.53 370.89 ± 37.70 277.49 ± 38.92 320.45 ± 63.12
  Treated 70.83 ± 10.59 125.1 ± 10.68 146.37 ± 17.89† 138.96 ± 14.86† 101.99 ± 27.71† 121.79 ± 38.25† 90.39 ± 14.58†
N = serum BUN and Cr in normal white rabbits; 0 hour = BUN and Cr levels at the end of ischemia; 2 hours = BUN and Cr levels at 2 hours
after renal reperfusion, etc.
*Data are mean ± standard deviation.
†BUN and Cr comparison between control and treated groups, p<0.01.
Table 3. Urine volume at the end of 2, 4, 6, 8, and 10 hours of reperfusion.
  Urine volume (mL) at designed time phases*
Group 0-2 hours 2-4 hours 4-6 hours 6-8 hours 8-10 hours
Control 3.55 ± 0.24 0.40 ± 0.03 0.15 ± 0.04 9.99 ±1.53 2.19 ± 0.26
Treated 4.92 ± 1.90 10.06 ± 2.87† 28.56 ± 2.15† 16.40 ± 1.01† 9.91 ± 2.51†
*Data are mean ± standard deviation.
†Urine volume comparison between control and treated groups, p<0.01.
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1). After 60 minutes of reperfusion in the control group,
three of seven rabbits remained anuria. However, in the
treated group, three of seven rabbits had urine flow after
30 minutes of reperfusion, and after 60 minutes, all seven
had urine flow, suggesting that an appropriate dose of
dexamethasone could mitigate tissue injury. It was
inferred that CRP was involved in the pathogenesis of
acute renal ischemic-reperfusion injury. Blocking early
CRP-mediated inflammatory reaction may have
therapeutic implications in improving the prognosis of
ARF with severe ischemic-reperfusion injury. There are
reports showing that dexamethasone has a renal
protective effect (15), but its specific mechanism remains
obscure. This study demonstrates that dexamethasone
could decrease CRP production significantly, which may
indicate that decreased production of CRP is one of its
renal protective mechanisms. However, after10 hours of
reperfusion, urine volume diminished despite an
unremarkable increase of CRP. Serum BUN and Cr also
worsened. The explanation for this phenomenon deserves
further investigation.
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